Search

Your search keyword '"Wiechen, Kai"' showing total 22 results
Start Over Author "Wiechen, Kai"
22 results on '"Wiechen, Kai"'

3. Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.

Author

Sahin, Ugur, primary, Tureci, Özlem, additional, Manikhas, Georgy M., additional, Lordick, Florian, additional, Rusyn, Andriy, additional, Vynnychenko, Ihor, additional, Dudov, Assen, additional, Bazin, Igor, additional, Bondarenko, Igor, additional, Melichar, Bohuslav, additional, Dhaene, Karl, additional, Wiechen, Kai, additional, Maurus, Daniel, additional, Schuler, Martin H., additional, and Al-Batran, Salah-Eddin, additional

Published
2019
Full Text
View/download PDF

4. Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction, and esophageal cancers: Results from the FAST study.

Author

Schuler, Martin H., primary, Al-Batran, Salah-Eddin, additional, Zvirbule, Zanete, additional, Manikhas, Georgy, additional, Lordick, Florian, additional, Rusyn, Andriy V., additional, Vynnychenko, Ihor, additional, Dudov, Assen, additional, Bazin, Igor, additional, Melichar, Bohuslav, additional, Dhaene, Karl, additional, Wiechen, Kai, additional, Maurus, Daniel, additional, Tureci, Özlem, additional, and Sahin, Ugur, additional

Published
2017
Full Text
View/download PDF

8. Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer

Author

Dahl, Edgar, primary, Sadr-Nabavi, Ariane, additional, Klopocki, Eva, additional, Betz, Beate, additional, Grube, Susanne, additional, Kreutzfeld, Rene, additional, Himmelfarb, Marina, additional, An, Han-Xiang, additional, Gelling, Stephen, additional, Klaman, Irina, additional, Hinzmann, Bernd, additional, Kristiansen, Glen, additional, Grützmann, Robert, additional, Kuner, Ruprecht, additional, Petschke, Beate, additional, Rhiem, Kerstin, additional, Wiechen, Kai, additional, Sers, Christine, additional, Wiestler, Otmar, additional, Schneider, Achim, additional, Höfler, Heinz, additional, Nährig, Jörg, additional, Dietel, Manfred, additional, Schäfer, Reinhold, additional, Rosenthal, André, additional, Schmutzler, Rita, additional, Dürst, Matthias, additional, Meindl, Alfons, additional, and Niederacher, Dieter, additional

Published
2004
Full Text
View/download PDF

9. Gene expression profiling in RAS oncogene-transformed cell lines and in solid tumors using subtractive suppression hybridization and cDNA arrays

Author

Sers, Christine, primary, Tchernitsa, Oleg I., additional, Zuber, Johannes, additional, Diatchenko, Luda, additional, Zhumabayeva, Bakhyt, additional, Desai, Sejal, additional, Htun, Sai, additional, Hyder, Karim, additional, Wiechen, Kai, additional, Agoulnik, Alexander, additional, Scharff, K.Michael, additional, Siebert, Paul D., additional, and Schäfer, Reinhold, additional

Published
2002
Full Text
View/download PDF

12. c-erbB-2 Antisense Oligonucleotides Inhibit Serum-Induced Cell Spreading of Ovarian Cancer Cells.

Author

Walker, John M., Bartlett, John M. S., and Wiechen, Kai

Abstract

Amplification or overexpression of the c-erbB-2 oncogene (also known as HER-2, neu) is a frequent event in many types of human cancer including 20-30% of ovarian cancers where it characterizes a group of patients with poor prognosis (1,2). The expression of p185 (c-erbB-2) is in contrast quite restricted in normal adult tissues (3). The c-erbB-2 oncogene product (p185c-erbB-2) is a growth factor receptor (GFR) with extensive homology to the receptor for the epidermal growth factor (EGFR) and the c-erbB-3 and c-erbB-4 gene products (4). According to the hypothesis that c-erbB-2 is involved in pathogenesis and progression of human cancer, the overexpression in fibroblasts leads to the appearance of a transformed phenotype, capable of forming colonies in soft agar and inducing tumors in mice (5). [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

20. Caveolin-1Is Down-Regulated in Human Ovarian Carcinoma and Acts as a Candidate Tumor Suppressor Gene

Author

Wiechen, Kai, Diatchenko, Luda, Agoulnik, Alexander, Scharff, K. Michael, Schober, Hagen, Arlt, Katharina, Zhumabayeva, Bakhyt, Siebert, Paul D., Dietel, Manfred, Schäfer, Reinhold, and Sers, Christine

Abstract

To identify novel markers differentially expressed in ovarian cancer versusnormal ovary, we hybridized microarrays with cDNAs derived from normal human ovaries and advanced stage ovarian carcinomas. This analysis revealed down-regulation of thecaveolin-1gene (CAV1) in ovarian carcinoma samples. Suppression of CAV1in ovarian carcinomas was confirmed using a tumor tissue array consisting of 68 cDNA pools from different matched human tumor and normal tissues. Immunohistochemistry demonstrated expression of caveolin-1 in normal and benign ovarian epithelial cells, but loss of expression in serous ovarian carcinomas. In low-grade carcinomas, redistribution of caveolin-1 from a membrane-associated pattern observed in normal epithelium to a cytoplasmic localization pattern was observed. No expression of caveolin-1 was detectable in four of six ovarian carcinoma cell lines investigated. In SKOV-3 and ES-2 carcinoma cells, which express high levels of the caveolin-1 protein, phosphorylation of the 22-kd caveolin-1 isoform was detected. Inhibition of both DNA methylation and histone deacetylation using 5-aza-2′deoxycytidine and Trichostatin A, respectively, relieves down-regulation of caveolin-1 in OAW42 and OVCAR-3 cells which is in part mediated by direct regulation at the mRNA level. Expression of CAV1in the ovarian carcinoma cell line OVCAR-3, resulted in suppression of tumor cell survival in vitro, suggesting that theCAV1gene is likely to act as a tumor suppressor gene in human ovarian epithelium.

Published
2001
Full Text
View/download PDF

21. Involvement of the c-<TOGGLE>erb</TOGGLE>B-2 oncogene product in the egf-induced cell motility of sk-ov-3 ovarian cancer cells

Author

Wiechen, Kai, Karaaslan, Selma, and Dietel, Manfred

Abstract

The epidermal growth factor (EGF) induces the rapid formation of dendritic processes and the dissociation of SK-OV-3 ovarian cancer cells. The SK-OV-3 cell line is characterized by over-expression of the c-erbB-2 oncogene product (p185c-erbB-2). To investigate the role of p185c-erbB-2 in cell motility, a c-erbB-2-specific single-chain antibody was expressed in SK-OV-3 cells using a retroviral expression vector. Eight individual clones expressing the single chain antibody were isolated. These clones have prominent retention of the cell-surface p185c-erbB-2. The EGF-induced morphologic changes and cell motility of the single-chain-antibody-expressing clones were strongly inhibited, as observed in cell dissociation and in transmigration experiments. However, the suppression of p185c-erbB-2 does not inhibit the motility signal elicited by 12-O-tetradecanoyl-phorbol-13-acetate. These data indicate that the c-erbB-2 oncogene product is essential to mediate the motility signal of EGF to SK-OV-3 ovarian cancer cells. The enhancement of tumor-cell motility may be partially responsible for the unfavorable prognosis of ovarian cancer with over-expression of c-erbB-2. Int. J. Cancer 83:409–414, 1999. © 1999 Wiley-Liss, Inc.

Published
1999
Full Text
View/download PDF

22. Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer.

Author

Dahl E, Sadr-Nabavi A, Klopocki E, Betz B, Grube S, Kreutzfeld R, Himmelfarb M, An HX, Gelling S, Klaman I, Hinzmann B, Kristiansen G, Grützmann R, Kuner R, Petschke B, Rhiem K, Wiechen K, Sers C, Wiestler O, Schneider A, Höfler H, Nährig J, Dietel M, Schäfer R, Rosenthal A, Schmutzler R, Dürst M, Meindl A, and Niederacher D

Subjects
Carcinoma, Ductal, Breast genetics, DNA, Complementary genetics, DNA, Neoplasm genetics, Expressed Sequence Tags, Female, Gene Expression Profiling, Genetic Markers, Humans, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Ovarian Neoplasms metabolism, Reverse Transcriptase Polymerase Chain Reaction methods, Breast Neoplasms genetics, Gene Expression Regulation, Neoplastic, Ovarian Neoplasms genetics
Abstract

The identification of novel disease-associated genes in gynaecological tumours has important implications for understanding the process of tumourigenesis and the development of novel treatment regimens. cDNA libraries from disease tissues may represent a valuable source to identify such genes. Recently, a bio-informatic procedure based on an 'electronic Northern' approach was established to screen expressed sequence tag (EST) libraries for genes differentially expressed in tumour and normal tissues, and identified 450 candidate genes differentially expressed in breast and ovarian cancer. In this report, the validation of an initial set of 40 candidate genes, which were selected due to their localization in chromosomal regions frequently altered in gynaecological tumours, is described. Differential expression of 29 of these genes, including three uncharacterized novel genes, was confirmed by applying cancer profiling arrays with 106 matched pairs of tumour/normal cDNAs and quantitative reverse transcription-polymerase chain reaction (RT-PCR) on 60 clinical specimens. The majority of these differentially expressed genes have not been described previously in the context of breast and ovarian cancer, and may constitute novel diagnostic markers for these tumour entities.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results